| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.2 | 4e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.2 | 7e-05 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.22 | 0.0001 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0004 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.21 | 0.0005 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0007 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.002 |